Skip to main content
. 2020 Oct 8;46(2):413–422. doi: 10.1038/s41386-020-00876-5

Fig. 5. The effectiveness of ABM300 is recapitulated in a second, distinct, mouse model of hyperdopaminergia, the DATKO model, with additional restoration of sensorimotor deficits.

Fig. 5

ABM300 (10 mg/kg) decreases novelty-induced hyperactivity (total distance traveled; cm) (a), aberrant stereotypic movements (b), and mania-like vertical exploration (c) in the open-field test. ABM300 ameliorates sensorimotor gating deficits (d), rescuing the PPI deficit at 16 dB pre-pulse. All tests balanced for sex, drugs administered 30 min before test via i.p. Data shown as mean ± SEM, *p ≤ 0.05 compared to vehicle (within genotype), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, two-way ANOVA, multiple comparisons, post-hoc Sidak’s test. a Effect of genotype F[1,43] = 116.9, p < 0.0001, effect of drug F[1,43] = 13.89, p = 0.0006, interaction of genotype x drug F[1,43] = 9.384, p = 0.0038. b Effect of genotype F[1,43] = 40.18, p < 0.0001 and effect of drug F[1,43] = 14.22, p = 0.0005, c Effect of genotype F[1,42] = 36.03, p < 0.0001, effect of drug F[1,42] = 19.16, p < 0.0001, interaction of genotype x drug F[1,42] = 10.80, p = 0.0021, d (4 dB) effect of genotype F[1,43] = 8.509, p = 0.0056, (8 dB) effect of genotype F[1,43] = 7.303, p = 0.0098, (16 dB) effect of genotype F[1,43] = 4.713, p = 0.0355.